JP5386499B2 - 動物の毛と選択的に結合する抗体および動物用の抗体ベースの薬物デリバリーシステム - Google Patents

動物の毛と選択的に結合する抗体および動物用の抗体ベースの薬物デリバリーシステム Download PDF

Info

Publication number
JP5386499B2
JP5386499B2 JP2010532477A JP2010532477A JP5386499B2 JP 5386499 B2 JP5386499 B2 JP 5386499B2 JP 2010532477 A JP2010532477 A JP 2010532477A JP 2010532477 A JP2010532477 A JP 2010532477A JP 5386499 B2 JP5386499 B2 JP 5386499B2
Authority
JP
Japan
Prior art keywords
hair
antibody
antibodies
binding
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010532477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502178A5 (https=
JP2011502178A (ja
Inventor
シュテファン・ホフマン
ハンス−ユルゲン・ハマン
ライナー・フィッシャー
シュテファン・シルベルク
ジモン・オリヴァー・フォーゲル
ヘルガ・シンケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of JP2011502178A publication Critical patent/JP2011502178A/ja
Publication of JP2011502178A5 publication Critical patent/JP2011502178A5/ja
Application granted granted Critical
Publication of JP5386499B2 publication Critical patent/JP5386499B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2010532477A 2007-11-02 2008-10-29 動物の毛と選択的に結合する抗体および動物用の抗体ベースの薬物デリバリーシステム Expired - Fee Related JP5386499B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07021396 2007-11-02
EP07021396.2 2007-11-02
PCT/EP2008/009110 WO2009056280A1 (en) 2007-11-02 2008-10-29 Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals

Publications (3)

Publication Number Publication Date
JP2011502178A JP2011502178A (ja) 2011-01-20
JP2011502178A5 JP2011502178A5 (https=) 2011-12-15
JP5386499B2 true JP5386499B2 (ja) 2014-01-15

Family

ID=40157719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532477A Expired - Fee Related JP5386499B2 (ja) 2007-11-02 2008-10-29 動物の毛と選択的に結合する抗体および動物用の抗体ベースの薬物デリバリーシステム

Country Status (9)

Country Link
US (1) US20110263826A1 (https=)
EP (1) EP2207806B1 (https=)
JP (1) JP5386499B2 (https=)
KR (2) KR20150138405A (https=)
CN (1) CN101910198B (https=)
AU (1) AU2008317953B2 (https=)
CA (1) CA2704024C (https=)
NZ (1) NZ585004A (https=)
WO (1) WO2009056280A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2550863A1 (de) 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987161A (en) * 1974-06-19 1976-10-19 The Procter & Gamble Company Composition and method for conditioning hair with hair antiserum
BR9106124A (pt) * 1990-03-05 1992-12-01 Coopers Animal Health Composicao parasiticida para aplicacao topica e processo de controlar a infestacao de ectoparasitas em hospedeiros mamiferos,domesticos,nao humanos
JP2879947B2 (ja) * 1990-06-04 1999-04-05 鐘紡株式会社 毛髪改質剤
JPH06227955A (ja) * 1992-12-08 1994-08-16 Kanebo Ltd 染毛剤又は化粧料及び前処理剤並びに染毛方法
EP0673638A3 (en) * 1994-03-24 1996-10-16 Kao Corp Cosmetic composition containing antibodies.
US7067499B2 (en) * 2002-05-06 2006-06-27 Hercules Incorporated Cationic polymer composition and its use in conditioning applications

Also Published As

Publication number Publication date
KR20150138405A (ko) 2015-12-09
CN101910198A (zh) 2010-12-08
EP2207806A1 (en) 2010-07-21
EP2207806B1 (en) 2013-04-10
KR20100102103A (ko) 2010-09-20
AU2008317953A1 (en) 2009-05-07
JP2011502178A (ja) 2011-01-20
CA2704024C (en) 2016-05-31
CA2704024A1 (en) 2009-05-07
WO2009056280A8 (en) 2010-06-10
AU2008317953B2 (en) 2014-03-20
CN101910198B (zh) 2014-10-29
US20110263826A1 (en) 2011-10-27
WO2009056280A1 (en) 2009-05-07
HK1151300A1 (en) 2012-01-27
NZ585004A (en) 2012-04-27

Similar Documents

Publication Publication Date Title
Coles Anthelmintic resistance–looking to the future: a UK perspective
Jongejan et al. Novel foci of Dermacentor reticulatus ticks infected with Babesia canis and Babesia caballi in the Netherlands and in Belgium
Kijlstra et al. The role of rodents and shrews in the transmission of Toxoplasma gondii to pigs
Coles Sustainable use of anthelmintics in grazing animals
Gharbi et al. A review of Hyalomma scupense (Acari, Ixodidae) in the Maghreb region: from biology to control
Egerton et al. Eradication of virulent footrot from sheep and goats in an endemic area of Nepal and an evaluation of specific vaccination
Kotze et al. Control of sheep flystrike: what's been tried in the past and where to from here
Coelho et al. Risk factors for Brucella spp. in domestic and wild animals
Bechert et al. Effects of two porcine zona pellucida immunocontraceptive vaccines on ovarian activity in horses
Lechat et al. Comparative evaluation of the prophylactic activity of a slow-release insecticide collar and a moxidectin spot-on formulation against Thelazia callipaeda infection in naturally exposed dogs in France
Coelho et al. Risk factors for brucella spp
Bradley et al. Vaccines for fertility regulation of wild and domestic species
JP5386499B2 (ja) 動物の毛と選択的に結合する抗体および動物用の抗体ベースの薬物デリバリーシステム
Malli et al. Quantifying the venom dose of the spider Cupiennius salei using monoclonal antibodies
Mody et al. Characterization of the biodistribution of a silica vesicle nanovaccine carrying a Rhipicephalus (Boophilus) microplus protective antigen with in vivo live animal imaging
Rodríguez et al. The occurrence of Sarcocystis spp. in the myocardium of alpacas (Vicugna pacos) with associated risk factors in the Peruvian Andes
JP6073239B2 (ja) 抗原隠蔽剤としての使用のための、ヒトラクトフェリン誘導ペプチド
AU2020202611A1 (en) Binding moieties for biofilm remediation
Otranto et al. Screening of commercial milk samples using ELISA for immuno-epidemiological evidence of infection by the cattle grub (Diptera: Oestridae)
Morales et al. Recombinant S3Pvac-phage anticysticercosis vaccine: Simultaneous protection against cysticercosis and hydatid disease in rural pigs
White A diagnostic approach to the pruritic horse
HK1151300B (en) Antibodies which bind selectively to hair of animals and an antibody based drug delivery system for animals
McDowell et al. Application of pharmaceutical drug delivery for biological control of the common brushtail possum in New Zealand: a review
Hinds et al. Feasibility of immunocontraception for managing stoats in New Zealand
Jones Phage-GnRH Constructs for Population Control of Feral Animals: Evaluation in Cats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111026

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120117

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20121127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131007

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees